Zih Yuan Tang

Zih Yuan Tang Biotechnology is a Taiwan-based biopharmaceutical company specializing in the development of botanical drugs and traditional medicine-derived therapeutics. The company is best known for its lead candidate, ZY-19, which was developed as a treatment for COVID-19 to prevent progression to severe disease and manage lung inflammation. Zih Yuan Tang utilizes a modern pharmacological approach to validate traditional herbal formulations, focusing on standardized extraction and clinical efficacy. The company's primary therapeutic focus lies in infectious diseases and respiratory conditions, bridging the gap between traditional knowledge and modern regulatory standards.